Allosteric modulation of alpha4beta2 nicotinic acetylcholine receptors by HEPES.
A number of new positive allosteric modulators (PAMs) have been reported that enhance responses of neuronal alpha7 and alpha4beta2 nicotinic acetylcholine receptor subtypes to orthosteric ligands. PAMs represent promising new leads for the development of therapeutic agents for disorders involving alterations in nicotinic neurotransmission including Autism, Alzheimer's and Parkinson's disease. During our recent studies of alpha4beta2 PAMs, we identified a novel effect of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES). The effects of HEPES were evaluated in a phosphate buffered recording solution using two-electrode voltage clamp techniques and alpha4beta2 and alpha7 nicotinic acetylcholine receptor subtypes expressed in Xenopus laevis oocytes. Acetylcholine induced responses of high-sensitivity alpha4beta2 receptors were potentiated 190% by co-exposure to HEPES. Responses were inhibited at higher concentrations (bell-shaped concentration/response curve). Coincidentally, at concentrations of HEPES typically used in oocyte recording (5-10mM), the potentiating effects of HEPES are matched by its inhibitory effects, thus producing no net effect. Mutagenesis results suggest HEPES potentiates the high-sensitivity stoichiometry of the alpha4beta2 receptors through action at the beta2+/beta2- interface and is dependent on residue beta2D218. HEPES did not potentiate low-sensitivity alpha4beta2 receptors and did not produce any observable effect on acetylcholine induced responses on alpha7 nicotinic acetylcholine receptors.
Department of Chemistry and Biochemistry, University of Alaska Fairbanks Fairbank, AK 99775, USA.
Maegan M
MM
Weltzin
Department of Chemistry and Biochemistry, University of Alaska Fairbanks Fairbank, AK 99775, USA.
Yanzhou
Y
Huang
Department of Chemistry and Biochemistry, University of Alaska Fairbanks Fairbank, AK 99775, USA. Electronic address: mkschulte@alaska.edu.
Marvin K
MK
Schulte
D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D005260:Female; D006531:HEPES / Q000494:pharmacology*; D006801:Humans; D006842:Hydrocarbons, Brominated / Q000494:pharmacology; D026121:Indole Alkaloids / Q000494:pharmacology; D018722:Nicotinic Agonists / Q000494:pharmacology*; D009865:Oocytes / Q000187:drug effects / Q000378:metabolism; D018408:Patch-Clamp Techniques; D011978:Receptors, Nicotinic / Q000187:drug effects*; D014982:Xenopus laevis
D006842:Hydrocarbons, Brominated; D026121:Indole Alkaloids; D018722:Nicotinic Agonists; D011978:Receptors, Nicotinic; C524215:desformylflustrabromine; C403531:nicotinic receptor alpha4beta2; D000109:Acetylcholine; D006531:HEPES